Management of Advanced Thyroid Cancer: Anaplastic Carcinoma.

2001 ◽  
Vol 52 (2) ◽  
pp. 149-153
Author(s):  
Katsuhiro Hirakawa ◽  
Koji Yajin ◽  
Takaharu Tatsukawa
Keyword(s):  
Thyroid Cancer ◽  
Anaplastic Carcinoma ◽  
Advanced Thyroid Cancer

Retrospective review of patients treated with intensity modulated radiation therapy (IMRT) with or without concurrent chemotherapy for locally advanced thyroid cancer: The Dana-Farber experience.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e16060-e16060
Author(s):  
Swati Kodali ◽  
Sewanti Atul Limaye ◽  
Aditya V. Shreenivas ◽  
Dave Zhao ◽  
Jochen H. Lorch ◽  
...  
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Local Control ◽  
Locally Advanced ◽  
Medullary Carcinoma ◽  
Concurrent Chemotherapy ◽  
Anaplastic Carcinoma ◽  
Regional Control ◽  
Locally Recurrent ◽  
Advanced Thyroid Cancer

e16060 Background: Chemotherapy has been used concurrently with radiation for local control as adjuvant treatment or for locally recurrent thyroid cancer. We present our experience using IMRT with or without sensitizing concurrent chemotherapy in this setting. Methods: All patients with thyroid carcinoma with or without minimal metastatic disease treated since 2005 at DFCI were reviewed. We collected data and analyzed the outcomes of patients treated with IMRT with or without concurrent chemotherapy for local control. Results: Twenty-two patients were identified: 13 Males, 9 Female, Median age 60 years There were 11 papillary, 6 medullary, 4 anaplastic, and1 follicular. Thirteen patients were treated adjuvantly, seven for locally recurrent disease and two definitively for unresectable disease. All patients with papillary and follicular thyroid cancer had prior surgery and radioactive iodine therapy. Patients with medullary carcinoma had surgery alone. Two patients with anaplastic carcinoma had surgery and two were found to be unresectable.. Seventeen patients received concurrent weekly carboplatin AUC1.5 and paclitaxel 30mg/m2 with radiation. Five patients did not receive any concurrent chemotherapy and were treated with radiotherapy alone. Radiation fields encompassed the thyroid bed, bilateral neck and in some cases the mediastinum. The radiation dose ranged from 5600cGy to 6600cGy. Mean follow up was 42 months. The overall survival at 36 months was 89.5% (95% CI, 76.7-100). Two patients with unresectable anaplastic thyroid cancer died from progressive disease. Loco-regional control rate at 36 months was 78.9% (95% CI, 62.6-99.6). No grade 3 or 4 toxicities were reported during treatment. Conclusions: IMRT with or without concurrent chemotherapy provided excellent loco regional control and might have contributed to improved overall survival in patients with locally advanced thyroid cancer.

Phase II study: aclarubicin in advanced thyroid cancer

1988 ◽  
Vol 117 (4_Suppl) ◽  
pp. S144
Author(s):  
H. SAMONIGG ◽  
D.K. HOSSFELD ◽  
J. SPEHN ◽  
H. FILL ◽  
G. LEB
Keyword(s):  
Thyroid Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Thyroid Cancer

scholarly journals Thyroid cancer overdiagnosis and overtreatment: a cross- sectional study at a thyroid cancer referral center in Ecuador

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Paola Solis-Pazmino ◽  
Jorge Salazar-Vega ◽  
Eddy Lincango-Naranjo ◽  
Cristhian Garcia ◽  
Gabriela Jaramillo Koupermann ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Mortality ◽  
Incidental Finding ◽  
Cross Sectional Study ◽  
Anaplastic Carcinoma ◽  
Treatment Modalities ◽  
Sectional Study ◽  
Cross Sectional ◽  
Referral Center ◽  
Clinical Records

Abstract Background In contrast to the rapid increase in thyroid cancer incidence, the mortality has remained low and stable over the last decades. In Ecuador, however, thyroid cancer mortality has increased. The objective of this study is to determine possible drivers of high rates of thyroid cancer mortality, through a cross-sectional analysis of all patients attending a thyroid cancer referral center in Ecuador. Methods From June 2014 to December 2017, a cross-sectional study was conducted at the Hospital de Especialidades Eugenio Espejo, a regional reference public hospital for endocrine neoplasia in adults in Quito, Ecuador. We identified the mechanism of detection, histopathology and treatment modalities from a patient interview and review of clinical records. Results Among 452 patients, 74.8% were young adults and 94.2% (426) were female. 13.7% had a family history of thyroid cancer, and patients’ median tumor size was 2 cm. The incidental finding was 54.2% whereas 45.8% was non-incidental. Thyroid cancer histology reported that 93.3% had papillary thyroid cancer (PTC), 2.7% follicular, 1.5% Hurtle cells, 1.6% medullary, 0.7% poor differentiated, and 0.2% anaplastic carcinoma. The mean MACIS (metastasis, age, completeness, invasion, and size) score was 4.95 (CI 4.15–5.95) with 76.2% of the thyroid cancer patients having MACIS score less than or equal to 6. The very low and low risk of recurrence was 18.1% (79) and 62% (271) respectively. An analysis of 319 patients with non-metastatic thyroid cancer showed that 10.7% (34) of patients had surgical complications. Moreover, around 62.5% (80 from 128 patients with thyroglobulin laboratory results) of TC patients had a stimulated-thyroglobulin value equal or higher than 2 ng/ml. Overall, a poor surgical outcome was present in 35.1% (112) patients. Out of 436 patients with differentiated thyroid carcinoma, 86% (375) received radioactive iodine. Conclusion Thyroid cancer histological characteristics and method of diagnosis are like those described in other reports without any evidence of the high frequency of aggressive thyroid cancer histology. However, we observed evidence of overtreatment and poor surgical outcomes that demand additional studies to understand their association with thyroid cancer mortality in Ecuador.

Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival

Endocrine ◽  
2020 ◽  
Author(s):  
Simone De Leo ◽  
Marta Di Stefano ◽  
Luca Persani ◽  
Laura Fugazzola ◽  
Carla Colombo
Keyword(s):  
Thyroid Cancer ◽  
Progression Free Survival ◽  
Line Treatment ◽  
First Line ◽  
Free Survival ◽  
Advanced Thyroid Cancer ◽  
First Line Treatment

Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer

1991 ◽  
Vol 14 (6) ◽  
pp. 475-480 ◽  
Author(s):  
Pietro De Besi ◽  
B. Busnardo ◽  
S. Toso ◽  
M. E. Girelli ◽  
D. Nacamulli ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Combined Chemotherapy ◽  
Advanced Thyroid Cancer
Sign in / Sign up

Export Citation Format

Share Document